Coagulation and Fibrinolysis

Question 1

Factors that are most prominent bleeding disorders that occur in patients who survive gestation and birth.

Answer 1

Factors 8 and 9

Question 2

Two critically important assemblies that are essential for normal hemostasis

Answer 2

tenase and prothrombinase

Question 3

Major inhibitor of tPA and TcuPA

Answer 3

Plasminogen activator inhibitor-1 (PAI-1)

Question 4

Most potent and highly selective inhibitor of plasmin.

Answer 4

α2-Antiplasmin

Question 5

Three major anticoagulant systems regulate the enzymes of the coagulation protein system to help to inhibit clot formation.

Answer 5

protein C/protein S system, the plasma serine protease inhibitor system

Question 6

Regulated by natural anticoagulants and the fibrinolytic system to avoid thrombus formation and extension

Answer 6

Coagulation

Question 7

Kunitz-type serine protease inhibitor

Answer 7

TFPI

Question 8

Main serine protease inhibitor of coagulation enzymes of the plasma serine protease inhibitor system

Answer 8

Antithrombin (antithrombin III)

Question 9

When activated, protein C, _____________________, is an enzyme that functions as an inhibitor

Answer 9

a 62-kDa vitamin K–dependent protein,

Question 10

Protein C is activated by thrombin when bound to an endothelial cell protein

Answer 10

Thrombomodulin

Question 11

A 69-kDa vitamin K–dependent protein, is not an enzyme

Answer 11

Protein S

Question 12

It is a cofactor, or receptor, for activated protein C on cell membranes.

Answer 12

Protein S

Question 13

Most potent inhibitor of FXIIa, kallikrein, and FXIa in plasma

Answer 13

C1 inhibitor
(C1 esterase inhibitor)

Question 14

Regulate the amount of free bradykinin in the intravascular compartment and reduce inflammatory events

Answer 14

C1 inhibitor (C1 esterase inhibitor)

Question 15

Causative factor for types I and II hereditary angioedema, a disorder associated with excessive bradykinin delivered to tissues.

Answer 15

C1 inhibitor

Question 16

Most potent inhibitor of the FVIIa–tissue factor complex.

Answer 16

Tissue Factor Pathway Inhibitor

Question 17

Only approximately ____% of TFPI circulates in plasma associated with lipoproteins

Answer 17

20%

Question 18

Cerebral anticoagulant

Answer 18

amyloid β-protein precursor (AβPP)

Question 19

Produce vasoactive hormones able to control the primary phase of hemostasis.

Answer 19

Endothelial cells

Question 20

Vasodilator, and it inhibits platelet aggregation

Answer 20

Prostacyclins (PGI2)

Question 21

Also known as cartilage oligomeric matrix protein (COMP)

Answer 21

Thrombospondin-5

Question 22

An extracellular protein able to control vascular tone

Answer 22

Thrombospondin-5

Question 23

Inhibits thrombin and acts as a natural anticoagulant in mice

Answer 23

COMP

Question 24

Determines a dose-dependent prolongation of thrombin time.

Answer 24

COMP

Question 25

TF is not fully active on intact cells; it becomes able to activate coagulation when cell membrane properties are modified.

Answer 25

Decryption” of “encrypted

Question 26

Two assays most commonly used to examine the coagulation system

Answer 26

APTT and PT

Question 27

Induced by surface (contact) activation of the system

Answer 27

APTT

Question 28

Induced by the addition of excess tissue factor

Answer 28

PT

Question 29

They are also referree to as "point of care” tests

Answer 29

APTT and PT

Question 30

Example of screening assay for primary hemostasis

Answer 30

Platelet count

Question 31

The recommended anticoagulant for APTT

Answer 31

3.2 g% sodium citrate

Question 32

Reversible chelator of calcium that prevents coagulation protein activation.

Answer 32

Sodium citrate

Question 33

Ratio of anticoagulant to whole blood

Answer 33

1 part anticoagulant to 9 parts whole blood

Question 34

APTT assesses the coagulation proteins: 2 pathways

Answer 34

intrinsic system and common pathways

Question 35

Serves as the basis for the international normalized ratio (INR) value used to monitor anticoagulation with warfarin or other vitamin-antagonists

Answer 35

PT

Question 36

Direct measure of fibrinogen function and may be used to ascertain if there is a defect in fibrinogen function

Answer 36

thrombin clotting time

Question 37

Abnormal protein fibrinogen

Answer 37

dysfibrinogenemia

Question 38

Measures the overall tendency of a plasma sample to form thrombin after initiation of coagulation

Answer 38

Thrombin Generation assay

Question 39

Plasma-based spectrophotometric global assay

Answer 39

Overall Hemostasis Potential

Question 40

Ancillary parameters of OHP

Answer 40

Overall coagulation potential and overall fibrinolytic potential